Find investors
← Back to all investors
Ben Dillon
ResearchedAngel Investors

Ben Dillon

Managing Director

Angel InvestorsSeed Round
Pitch Ben

Get their honest, personalized take on your startup.

Sign in to pitch Ben

At a glance

Full Name
Ben Dillon
Title
Managing Director
Firm
SK Capital Partners
Firm Type
Private investment firm (private equity — buyouts, recapitalizations, and growth equity)
Investment Stage
Middle-market buyout / growth equity (control and structured investments) — not seed/angel
Check Size
Firm invests out of institutional funds (SK Capital Partners Fund VI closed at ~$2.95B); individual deal equity typically ranges into the hundreds of millions
Target Company Profile
Established, cash-generative businesses in specialty materials, chemicals, life sciences, and pharmaceutical services; carve-outs, family/founder-owned companies, and platform build-ups
Sector Focus
Specialty materials, chemicals, and ingredients; life sciences and pharmaceuticals (including pharma services/CDMO)
Geographic Focus
North America and Europe (global portfolio)
Location
New York, New York, United States

Background

Ben Dillon is a Managing Director at SK Capital Partners, a New York–based private investment firm focused on the specialty materials, chemicals, ingredients, life sciences, and pharmaceutical sectors. He leads the firm's fundraising, investor relations, and co-investment activities, and is a founding member of SK Capital's Sustainability Committee. SK Capital was announced as his employer in May 2019, when he joined to lead investor relations and fundraising, working alongside longtime partner Jim Marden through a transition period into the end of that year.

Before SK Capital, Dillon spent 12 years as a Managing Director at Partners Group, where he was a member of the firm's Client Solutions team in the New York office. In that role he oversaw institutional investor relationships across Partners Group's investment funds, separate accounts, and co-investment programs. Earlier in his Partners Group tenure he spent roughly a year with the firm's private equity team as an associate based in Zug, Switzerland, and prior to that he worked as a financial analyst at a Chicago-based private equity firm.

Dillon holds a B.S. in Business Administration from Babson College and an MBA in Finance and Economics from the University of Chicago Booth School of Business. At the time of his hiring, SK Capital co-founder and Managing Director Barry Siadat described him as bringing "extensive experience serving sophisticated global investors" and providing "strong leadership in our mission to serve our investor base."

Note: aggregator/stub data labeling Ben Dillon an "Angel Investor" writing "Seed Round" checks appears to be inaccurate. His verified role is a private-equity Managing Director responsible for capital formation and LP relationships at an institutional buyout firm, not personal angel/seed investing.

Investment Thesis & Focus

  • SK Capital invests in specialty materials, chemicals, and ingredients and in life sciences / pharmaceuticals, pursuing buyouts, recapitalizations, and growth-equity investments in established, differentiated businesses.
  • The firm targets companies where it can drive operational improvement and growth — carve-outs from large corporates, founder/family-owned businesses, and platforms it can scale globally.
  • Dillon's own mandate is capital-side, not deal-sourcing: he leads fundraising, investor relations, and co-investment, serving the firm's institutional LP base and structuring co-investment opportunities alongside its funds.
  • Sustainability is an explicit part of the firm's approach — Dillon is a founding member of SK Capital's Sustainability Committee.
  • Scale of strategy: the firm reports managing roughly $7–8B in assets, with a portfolio generating approximately $15B in annual revenue, employing 20,000+ people across ~190 plants in 32 countries.

Notable Investments

  • Seqens — Acquired a majority shareholding in the France-based leader in pharmaceutical solutions and specialty ingredients (CDMO/specialty chemicals platform).
  • Swixx BioPharma AG — Definitive agreement announced December 2025 to invest in the specialty commercialization/pharma-services company to drive its next phase of growth and global expansion.
  • Catalent Blow-Fill-Seal Sterile CDMO business — Agreement to acquire Catalent's blow-fill-seal sterile contract development and manufacturing operations.
  • Valtris Specialty Chemicals — Specialty chemicals platform built and later sold by SK Capital (exit).

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.